Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review

References

• Johnson MJ, Yorke J, Hansen-Flaschen J, et al. Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic. Eur Respir J. 2017;50(3):1701297.
   PubMedGoogle Scholar
• Currow DC, Plummer JL, Crockett A, et al. A community population survey of prevalence and severity of dyspnea in adults. J Pain Symptom Manage. 2009;38(4):533–545.
   PubMed Web of Science ®Google Scholar
• Nicholls DA. The experience of chronic breathlessness. Physiother Theory Pract. 2003;19(3):123–136.
   Google Scholar
• Barnett M. Chronic obstructive pulmonary disease: a phenomenological study of patients’ experiences. J Clin Nurs. 2005;14(7):805–812.
   PubMed Web of Science ®Google Scholar
• Currow DC, Smith JM, Chansriwong P, et al. Missed opportunity? Worsening breathlessness as a harbinger of death: a cohort study. Eur Respir J. 2018;52(3):1800684.
   PubMed Web of Science ®Google Scholar
• Currow DC, Chang S, Reddel HK, et al. Breathlessness, anxiety, depression, and function-the BAD-F study: a cross-sectional and population prevalence study in adults. J Pain Symptom Manage. 2020;59(2):197–205.e2.
   PubMed Web of Science ®Google Scholar
• Currow DC, Dal Grande E, Ferreira D, et al. Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups. Thorax. 2017;72(12):1151–1153.
   PubMed Web of Science ®Google Scholar
• Currow DC, Chang S, Ferreira D, et al. Chronic breathlessness and sleep problems: a population-based survey. BMJ Open. 2021;11(8):e046425.
   PubMed Web of Science ®Google Scholar
• Kochovska S, Chang S, Morgan DD, et al. Activities forgone because of chronic breathlessness: a cross-sectional population prevalence study. Palliat Med Rep. 2020;1(1):166–170.
   PubMedGoogle Scholar
• Ekstrom M, Johnson MJ, Taylor B, et al. Breathlessness and sexual activity in older adults: the Australian longitudinal study of ageing. NPJ Prim Care Respir Med. 2018;28(1):20.
   PubMedGoogle Scholar
• Currow DC, Smith J, Davidson PM, et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage. 2010;39(4):680–690.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434–1440.
   PubMed Web of Science ®Google Scholar
• Tod AM, Joanne R. Overcoming delay in the diagnosis of lung cancer: a qualitative study. Nurs Stand. 2010;24(31):35–43.
   PubMedGoogle Scholar
• Hutchinson A, Pickering A, Williams P, et al. Breathlessness and presentation to the emergency department: a survey and clinical record review. BMC Pulm Med. 2017;17(1):53.
   PubMedGoogle Scholar
• Currow DC, Clark K, Mitchell GK, et al. Prospectively collected characteristics of adult patients, their consultations and outcomes as they report breathlessness when presenting to general practice in Australia. PLoS One. 2013;8(9):e74814.
   PubMed Web of Science ®Google Scholar
• Gysels M, Bausewein C, Higginson LJ. Experiences of breathlessness: a systematic review of the qualitative literature. Palliat Support Care. 2007;5(3):281–302.
   PubMedGoogle Scholar
• Marciniuk DD, Goodridge D, Hernandez P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(2):69–78.
   PubMed Web of Science ®Google Scholar
• Rocker GM, Sinuff T, Horton R, et al. Advanced chronic obstructive pulmonary disease: innovative approaches to palliation. J Palliat Med. 2007;10(3):783–797.
   PubMed Web of Science ®Google Scholar
• Bausewein C, Booth S, Gysels M, et al. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev. 2008;2008(2):CD005623
   Google Scholar
• Barnes-Harris M, Allgar V, Booth S, et al. Battery operated fan and chronic breathlessness: does it help? BMJ Support Palliat Care. 2019;9(4):478–481.
   PubMed Web of Science ®Google Scholar
• Maddocks M, Nolan CM, Man W, et al. Neuromuscular electrical stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(1):27–36.
   PubMed Web of Science ®Google Scholar
• Uronis HE, Ekstrom MP, Currow DC, et al. Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis. Thorax. 2015;70(5):492–494.
   PubMed Web of Science ®Google Scholar
• Jennings A, Davies AN, Higgins JPT, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939–944.
   PubMed Web of Science ®Google Scholar
• Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–528.
   PubMed Web of Science ®Google Scholar
• Oxberry SG, Torgerson DJ, Bland M, et al. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail. 2011;13(9):1006–1012.
   PubMed Web of Science ®Google Scholar
• Currow DC, McDonald C, Oaten S, et al., Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011:42(3):388–399.
   PubMed Web of Science ®Google Scholar
• Ekstrom M, Nilsson F, Abernethy AP, et al., Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc. 2015:12(7):1079–1092.
   PubMed Web of Science ®Google Scholar
• Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016;3(3):CD011008.
   PubMedGoogle Scholar
• Johnson MJ, Bland M, Oxverry SG, et al. Clinically important differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manage. 2013;46(6):957–963.
   PubMed Web of Science ®Google Scholar
• Currow DC, Louw S, McCloud P. Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial. Thorax. 2020;75(1):50–56.
   PubMed Web of Science ®Google Scholar
• Currow DC, Watts GJ, Johnson M, et al. A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. BMJ Open. 2017;7(7):e018100.
   PubMed Web of Science ®Google Scholar
• Verberkt CA, van den Beuken-van Everdingen MHJ, Schols J, et al., Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial. JAMA Intern Med. 2020:180(10):1306–1314.
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654.
   PubMed Web of Science ®Google Scholar
• Smid DE, Franssen FME, Houben-Wilke S, et al. Responsiveness and MCID estimates for CAT, CCQ, and HADS in patients with COPD undergoing pulmonary rehabilitation: a prospective analysis. J Am Med Dir Assoc. 2017;18(1):53–58.
   PubMed Web of Science ®Google Scholar
• Ekström M, Elmberg V, Lindow T, et al. Breathlessness measurement should be standardised for the level of exertion. Eur Respir J. 2018;51(5):1800486.
   PubMedGoogle Scholar
• Currow DC, Quinn S, Greene A, et al. The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea. J Palliat Med. 2013;16(8):881–886.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure–a pilot study. Eur J Heart Fail. 2002;4(6):753–756.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Cockayne S, Currow DC, et al. Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo-controlled trial. ESC Heart Fail. 2019;6(6):1149–1160.
   PubMed Web of Science ®Google Scholar
• Kestenbaum MG, Vilches AO, Messersmith S, et al. Alternative routes to oral opioid administration in palliative care: a review and clinical summary. Pain Med. 2014;15(7):1129–1153.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Silvershein DI. A comparison of long-and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84(7):602–612.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. JAMA. 2016;315(15):1624–1645.
   PubMed Web of Science ®Google Scholar
• Klepstad P, Kaasa S, Ase J, et al. Immediate-or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain. 2003;101(1):193–198.
   PubMed Web of Science ®Google Scholar
• Broomhead A, Kerr R, Tester W, et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage. 1997;14(2):63–73.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831–838.
   PubMed Web of Science ®Google Scholar
• Gourlay GK. Sustained relief of chronic pain. Clin Pharmacokinet. 1998;35(3):173–190.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Southan MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology. 1993;78(1):36–43.
   PubMed Web of Science ®Google Scholar
• Chen X, Moran T, Smallwood N. Real world opioid prescription to patients with serious, non-malignant, respiratory illnesses and chronic breathlessness. Intern Med J. 2022;52(11):1925–1933.
   PubMed Web of Science ®Google Scholar
• Rocker G, Young J, Donahue M, et al. Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. Cmaj. 2012;184(9):E497–504.
   PubMed Web of Science ®Google Scholar
• Janssen DJ, de Hosson SM, de Vaate E, et al. Attitudes toward opioids for refractory dyspnea in COPD among Dutch chest physicians. Chron Respir Dis. 2015;12(2):85–92.
   PubMed Web of Science ®Google Scholar
• Vozoris NT. Benzodiazepines and opioids need to be prescribed with caution in advanced COPD. Evid Based Med. 2014;19(5):170.
   PubMedGoogle Scholar
• Verberkt CA, van den Beuken-van Everdingen MHA, Schols JMGA, et al., Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. Eur Respir J. 2017:50(5):1701153.
   PubMed Web of Science ®Google Scholar
• Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014;348:g445.
   PubMed Web of Science ®Google Scholar
• Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016;48(3):683–693.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Currow DC. Opioids for breathlessness: a narrative review. BMJ Support Palliat Care. 2020;10(3):287–295.
   PubMed Web of Science ®Google Scholar
• Weir N, Fischer A, Good P. Assessing the practice of palliative care doctors: what driving advice do they give patients with advanced disease? Intern Med J. 2017;47(10):1161–1165.
   PubMed Web of Science ®Google Scholar
• Ferreira D. Regular, low-dose, sustained-release oral morphine for chronic breathlessness – building the evidence, in College of medicine and public health. Adelaide: Flinders University; 2022.
   Google Scholar
• Johnson MJ, Bland M, Oxberry SG, et al. Opioids for chronic refractory breathlessness: patient predictors of beneficial response. Eur Respir J. 2013;42(3):758–766.
   PubMed Web of Science ®Google Scholar
• Ferreira DH, Ekstrom M, Sajkov D, et al. Extended-release morphine for chronic breathlessness in pulmonary arterial hypertension—A randomized, double-blind, placebo-controlled, crossover study. J Pain Symptom Manage. 2018;56(4):483–492.
   PubMed Web of Science ®Google Scholar
• Abdallah SJ, Wilkinson-Maitland C, Saad N, et al. Effect of morphine on breathlessness and exercise endurance in advanced COPD: a randomised crossover trial. Eur Respir J. 2017;50(4):1701235.
   PubMed Web of Science ®Google Scholar
• Verberkt CA, van den Beuken-Everdingen MH, Schols JM, et al. Morphine for chronic breathlessness in COPD: improvement predictors—cross-sectional study. BMJ Support Palliat Care. 2022; bmjspcare-2022-003693. DOI:10.1136/spcare-2022-003693.
   PubMed Web of Science ®Google Scholar
• Esser RW, Stoeckel CM, Kirsten A, et al. Structural brain changes in patients with COPD. Chest. 2016;149(2):426–434.
   PubMed Web of Science ®Google Scholar
• Abdallah SJ, Faull OK, Wanigasekera V, et al. Opioids for breathlessness: psychological and neural factors influencing response variability. Eur Respir J. 2019;54(3):1900275.
   PubMed Web of Science ®Google Scholar
• Currow DC, Quinn S, Ekstrom M, et al. Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors? BMJ Open. 2015;5(5):e006818.
   PubMed Web of Science ®Google Scholar
• Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–452.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Selecky PA, Harrod CG, et al. American College of chest physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010;137(3):674–691.
   PubMed Web of Science ®Google Scholar
• GOLD, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease., G.I.f.C.O.L, Disease, Editor. 2021.
   Google Scholar
• Nishino T. Dyspnoea: underlying mechanisms and treatment. Br J Anaesth. 2011;106(4):463–474.
   PubMed Web of Science ®Google Scholar
• Schwartzstein RM, Simon PM, Weiss JW, et al. Breathlessness induced by dissociation between ventilation and chemical drive. Am Rev Respir Dis. 1989;139(5):1231–1237.
   PubMedGoogle Scholar
• O’Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis. 1993;148(5):1351–1357.
   PubMed Web of Science ®Google Scholar
• Banzett RB, Adams L, O’Donnell CR, et al. Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response. Am J Respir Crit Care Med. 2011;184(8):920–927.
   PubMed Web of Science ®Google Scholar
• Muers MF. Opioids for dyspnoea. Thorax. 2002;57(11):922–923.
   PubMed Web of Science ®Google Scholar
• Baumgärtner U, Buchholz HG, Bellosevich A, et al. High opiate receptor binding potential in the human lateral pain system. Neuroimage. 2006;30(3):692–699.
   PubMed Web of Science ®Google Scholar
• Farrell P, Kjaer M, Bach FW, et al. Beta‐endorphin and adrenocorticotropin response to supramaximal treadmill exercise in trained and untrained males. Acta Physiol Scand. 1987;130(4):619–625.
   PubMedGoogle Scholar
• Schwarz L, Kindermann W. Changes in β-endorphin levels in response to aerobic and anaerobic exercise. Sports Med. 1992;13(1):25–36.
   PubMed Web of Science ®Google Scholar
• Gifford AH, Mahler DA, Waterman LA, et al. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. J Chron Obstruc Pulmon Dis. 2011;8(3):160–166.
   Web of Science ®Google Scholar
• Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J. 2009;33(4):771–777.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Gifford AH, Waterman LA, et al. Effect of increased blood levels of β-endorphin on perception of breathlessness. Chest. 2013;143(5):1378–1385.
   PubMed Web of Science ®Google Scholar
• Currow DC, Hunt T, Louw S, et al. Isolating peripheral effects of endogenous opioids in modulating exertional breathlessness in people with moderate or severe COPD: a randomised controlled trial. ERJ Open Res. 2019;5(4):00153–2019.
   PubMedGoogle Scholar
• Sgherza AL, Axen K, Fain R, et al. Effect of naloxone on perceived exertion and exercise capacity during maximal cycle ergometry. J Appl Physiol. 2002;93(6):2023–2028.
   PubMed Web of Science ®Google Scholar
• Schlaepfer TE, Strain EC, Greennberg BD, et al. Site of opioid action in the human brain: mu and kappa agonists’ subjective and cerebral blood flow effects. Am J Psychiatry. 1998;155(4):470–473.
   PubMed Web of Science ®Google Scholar
• Pattinson KT, Governo RJ, MacIntosh BJ, et al. Opioids depress cortical centers responsible for the volitional control of respiration. J Neurosci. 2009;29(25):8177–8186.
   PubMed Web of Science ®Google Scholar
• Hayen A, Wanigasekera V, Faull OK, et al. Opioid suppression of conditioned anticipatory brain responses to breathlessness. Neuroimage. 2017;150:383–394.
   PubMed Web of Science ®Google Scholar
• Krajnik M, Jassem E, Sobanski P. Opioid receptor bronchial tree: current science. Curr Opin Support Palliat Care. 2014;8(3):191–199.
   PubMed Web of Science ®Google Scholar
• Kamikawa Y, Shimo Y. Morphine and opioid peptides selectively inhibit the non-cholinergically mediated neurogenic contraction of Guinea-pig isolated bronchial muscle. J Pharm Pharmacol. 1990;42(3):214–216.
   PubMed Web of Science ®Google Scholar
• Milne KM, Ibrahim-Masthan M, Scheeren RE, et al. Inspiratory neural drive and dyspnea in interstitial lung disease: effect of inhaled fentanyl. Respir Physiol Neurobiol. 2020;282:103511.
   PubMed Web of Science ®Google Scholar
• Spathis A, Booth S, Moffat C, et al. The Breathing, Thinking, Functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. NPJ Prim Care Respir Med. 2017;27(1):27.
   PubMedGoogle Scholar
• O’Donnell CR, Schwartzstein RM, Lansing RW, et al. Dyspnea affective response: comparing COPD patients with healthy volunteers and laboratory model with activities of daily living. BMC Pulm Med. 2013;13(1):27.
   PubMedGoogle Scholar
• Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10(10). doi:10.1002/14651858.CD007354.pub3
   PubMedGoogle Scholar
• Peoples AR, Bushunow PW, Garland SN, et al. Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. Support Care Cancer. 2016;24(3):1339–1347.
   PubMed Web of Science ®Google Scholar
• Dudgeon DJ, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage. 1998;16(4):212–219.
   PubMed Web of Science ®Google Scholar
• Yohannes AM, Willgoss TG, Baldwin RC, et al. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry. 2010;25(12):1209–1221.
   PubMed Web of Science ®Google Scholar
• Hutchinson A, Johnson MJ, Currow DC. Acute-on-chronic breathlessness: recognition and response. J Pain Symptom Manage. 2019;57(5):e4–e5.
   PubMed Web of Science ®Google Scholar
• Smallwood N, Thompson M, Wartrender-Sparkes M, et al. Integrated respiratory and palliative care may improve outcomes in advanced lung disease. ERJ Open Res. 2018;4(1):00102–2017.
   PubMedGoogle Scholar
• Fulton B, Brogden RN. Buspirone. Cns Drugs. 1997;7(1):68–88.
   Google Scholar
• Perna G, Cogo R, Bellodi L. Selective serotonin re‐uptake inhibitors beyond psychiatry: are they useful in the treatment of severe, chronic, obstructive pulmonary disease? Depress Anxiety. 2004;20(4):203–204.
   PubMed Web of Science ®Google Scholar
• Smoller JW, Pollack MH, Systrom D, et al. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics. 1998;39(1):24–29.
   PubMed Web of Science ®Google Scholar
• Lacasse Y, Beaudoin L, Rousseau L, et al. Randomized trial of paroxetine in end-stage COPD. Monaldi Arch Chest Dis. 2004;61(3):140–147.
   PubMedGoogle Scholar
• Eiser N, Harte R, Spiros K, et al. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD. 2005;2(2):233–241.
   PubMedGoogle Scholar
• Momtaz OM, Rabei SM, Tawfike NE, et al. Effect of treatment of depression and anxiety on physiological state of severe COPD patients. Egypt J Chest Dis Tuberculosis. 2015;64(1):29–34.
   Google Scholar
• Currow DC, Ekstrom M, Louw S, et al. Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial. Eur Respir J. 2019;53(1):1801270.
   PubMed Web of Science ®Google Scholar
• Nishino T, Ide T, Sudo T, et al. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med. 2000;161(6):1963–1967.
   PubMed Web of Science ®Google Scholar
• Minowa Y, Ide T, Nishino T. Effects of inhaled furosemide on CO2 ventilatory responsiveness in humans. Pulm Pharmacol Ther. 2002;15(4):363–368.
   PubMed Web of Science ®Google Scholar
• Moosavi SH, Binks AP, Lansing RW, et al. Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol. 2007;156(1):1–8.
   PubMed Web of Science ®Google Scholar
• Jensen D, Amjadi K, Harris-McAllister V, et al. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax. 2008;63(7):606–613.
   PubMed Web of Science ®Google Scholar
• Ong KC, Kor AC, Chong WF, et al. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169(9):1028–1033.
   PubMed Web of Science ®Google Scholar
• Vahedi H, Mahshidfar B, Rabiee H, et al. The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomized controlled clinical trial. Respir Care. 2013;58(11):1873–1877.
   PubMed Web of Science ®Google Scholar
• Lockhart A, Slutsky AS. Furosemide and loop diuretics in human asthma. Chest. 1994;106(1):244–249.
   PubMed Web of Science ®Google Scholar
• Verleden G, Pype JL, Deneffe G, et al. Effect of loop diuretics on cholinergic neurotransmission in human airways in vitro. Thorax. 1994;49(7):657–663.
   PubMed Web of Science ®Google Scholar
• Newton PJ, Davidson PM, Krum H, et al. The acute haemodynamic effect of nebulised furosemide in stable, advanced heart failure. Heart Lung Circ. 2012;21(5):260–266.
   PubMed Web of Science ®Google Scholar
• Kanezaki M, Terada K, Ebihara S. Effect of olfactory stimulation by L-menthol on laboratory-induced dyspnea in COPD. Chest. 2020;157(6):1455–1465.
   PubMed Web of Science ®Google Scholar
• Kanezaki M, Terada K, Ebihara S. l-Menthol - a new treatment for breathlessness? Curr Opin Support Palliat Care. 2021;15(4):233–238.
   PubMed Web of Science ®Google Scholar
• Plevkova J, Kollarik M, Poliacek I, et al. The role of trigeminal nasal TRPM8-expressing afferent neurons in the antitussive effects of menthol. J Appl Physiol. 2013;115(2):268–274.
   PubMed Web of Science ®Google Scholar
• Eccles R, Griffiths DH, Newton CG, et al. The effects of menthol isomers on nasal sensation of airflow. Clin Otolaryngol Allied Sci. 1988;13(1):25–29.
   PubMed Web of Science ®Google Scholar
• Pickering EE, Semple SJ, Nazir MS, et al. Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety. Chron Respir Dis. 2011;8(2):109–118.
   PubMed Web of Science ®Google Scholar
• Abdallah SJ, Smith BM, Ware MA, et al. Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease. A randomized controlled trial. Ann Am Thorac Soc. 2018;15(10):1146–1158.
   PubMed Web of Science ®Google Scholar
• S-Y L, Li JS, Wang MH, et al. Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study. BMC Complement Altern Med. 2012;12(1). doi: 10.1186/1472-6882-12-197
   Google Scholar
• Johnson MJ, Simpson MI, Currow DC, et al. Magnetoencephalography to investigate central perception of exercise-induced breathlessness in people with chronic lung disease: a feasibility pilot. BMJ Open. 2015;5(6):e007535.
   PubMed Web of Science ®Google Scholar
• Ferreira D, Kochovska S, Honson A, et al. Patients’ and their caregivers’ experiences with regular, low-dose, sustained-release morphine for chronic breathlessness associated with COPD: a qualitative study. BMJ Open Respir Res. 2022;9(1):e001210.
   PubMed Web of Science ®Google Scholar